News Mylan expects first US Herceptin biosimilar launch Deal with Roche paves way for near-copy of breast cancer blockbuster
News Mylan challenges Amgen's Neulasta in US Mylan and Biocon file biosimilar of white blood cell booster
News Teva's CEO Vigodman steps down Firm searches for new leader, chairman takes over on interim basis.
News Embattled Mylan files Herceptin biosimilar in US But senators call for investigation into EpiPen schools contracts.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.